Munuza (Tobramycin)

Tobramycin, the active ingredient in Munuza, is an aminoglycoside antibiotic presented as an inhalation formulation for the treatment of chronic Pseudomonas aeruginosa lung infections in cystic fibrosis patients. It is indicated for patients with cystic fibrosis who experience persistent bacterial colonisation, helping to reduce exacerbations and improve lung function.

GNH USA supplies Munuza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with all batches meeting EU pharmacopeial standards and delivered under strict quality assurance protocols.

Munuza (tobramycin) is used via inhalation to manage bacterial infections affecting the respiratory tract, particularly in cystic fibrosis.

Cystic fibrosis lung infection: decreases chronic Pseudomonas aeruginosa colonisation and helps maintain lung function. Chronic Pseudomonas aeruginosa infection: lowers bacterial burden in the airways and reduces exacerbation rates. Persistent respiratory infection in bronchiectasis: improves sputum clearance and reduces infection severity. Pseudomonas aeruginosa colonisation in patients with chronic lung disease: assists in long‑term bacterial control.

Inhaled tobramycin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Cough or throat irritation - Dysphonia (hoarse voice) - Bronchospasm or wheezing - Metallic taste in the mouth

Serious or Rare Side Effects: - Ototoxicity leading to hearing loss - Nephrotoxicity causing renal impairment - Severe allergic reactions, including anaphylaxis

Use of inhaled tobramycin requires careful monitoring to minimise risks. - Renal monitoring: assess kidney function before and during therapy. - Audiometric testing: evaluate hearing periodically due to risk of ototoxicity. - Respiratory assessment: monitor for bronchospasm and adjust inhalation technique as needed. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pregnancy and lactation: use only if benefits outweigh risks after consulting a prescriber. - Store at below 25°C: keep in the original pack, protect from moisture.

Tobramycin can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Loop diuretics (e.g., furosemide): increased risk of nephrotoxicity. - Other nephrotoxic agents (e.g., vancomycin, amphotericin B): additive kidney damage. - Neuromuscular blocking agents (e.g., curare): enhanced neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Cisplatin: heightened ototoxic risk. - Fluoroquinolones: potential antagonistic effect on antibacterial activity. - Antacids containing magnesium or aluminum: may affect absorption if oral formulation is used.